These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32345264)

  • 61. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
    Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program.
    Hernandez-Suarez DF; Tomassini-Fernandini JC; Cuevas A; Rosario-Berrios AN; Nuñez-Medina HJ; Padilla-Arroyo D; Rivera N; Liriano J; Vega-Roman RK; Renta JY; Melin K; Duconge J
    Int J Environ Res Public Health; 2018 May; 15(6):. PubMed ID: 29848980
    [No Abstract]   [Full Text] [Related]  

  • 63. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy].
    Muslimova EF; Afanasiev SA; Rebrova TY; Sergienko TN; Repin AN
    Ter Arkh; 2017; 89(5):74-78. PubMed ID: 28631703
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients.
    Yi X; Cheng W; Lin J; Zhou Q; Wang C
    J Stroke Cerebrovasc Dis; 2016 Sep; 25(9):2136-44. PubMed ID: 27318652
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
    Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
    Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile.
    Xu J; Wang A; Wangqin R; Mo J; Chen Z; Dai L; Meng X; Zhao X; Wang Y; Li H; Chen W; Xian Y; Wang Y;
    Ann Neurol; 2019 Sep; 86(3):419-426. PubMed ID: 31237713
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
    Chouchene S; Dabboubi R; Raddaoui H; Abroug H; Ben Hamda K; Hadj Fredj S; Abderrazak F; Gaaloul M; Rezek M; Neffeti F; Hellara I; Sassi M; Khefacha L; Sriha A; Nouira S; Najjar MF; Maatouk F; Messaoud T; Hassine M
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1567-1574. PubMed ID: 30073432
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
    Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
    Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort.
    Melin K; Moon JY; Qi Q; Hernandez-Suarez DF; Duconge J; Hua S; Gonzalez S; Zeng D; Kaplan RC
    Pharmacogenomics; 2019 Jan; 20(2):75-83. PubMed ID: 30520344
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
    Li G; Chen J; Xu Z; Wang Y; Ding N; Peng L; Zhang C; Shao Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Dec; 34(6):839-843. PubMed ID: 29188612
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy.
    Patel PD; Niu X; Shannon CN; Denny JC; Peterson JF; Fusco MR; Chitale RV
    Transl Stroke Res; 2022 Feb; 13(1):46-55. PubMed ID: 33611730
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.
    Li X; Wang Z; Wang Q; Xu Q; Lv Q
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):84-93. PubMed ID: 30098132
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease.
    Zhang YJ; Li DJ; Li ZY; Hu XL; Li H; Ma QL; Chen XP
    BMC Cardiovasc Disord; 2022 Dec; 22(1):575. PubMed ID: 36581799
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
    Sychev DA; Shprakh VV; Kitaeva EY; Mirzaev KB; Mickhalevich IM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(3. Vyp. 2):45-52. PubMed ID: 31184624
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interaction among CYP2C8, EPHX2, and CYP4A11 Gene Variants Significantly Increases the Risk for Ischemic Stroke in Chinese Populations.
    Yi X; Liao D; Fu X; Zhang B; Wang C
    J Atheroscler Thromb; 2015; 22(11):1148-57. PubMed ID: 25947240
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.